Precision BioSciences (NASDAQ:DTIL) saw its stock rise 5% following the announcement that the U.S. Food and Drug Administration (FDA) awarded Orphan Drug Designation to its PBGENE-DMD therapy for ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

Precision BioSciences is also currently evaluating PBGENE-PMM, a first-of-its-kind treatment for m.3243 associated mitochondrial disease, in pre-clinical studies.

Precision BioSciences’ most advanced cell therapy for a type of blood cancer is on track for a pivotal clinical trial, but that study is no longer its responsibility.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies w ...

DURHAM – Precision BioSciences, a genome-editing company based in Durham, announced today the opening of its highly prized production facility for in-house manufacturing of its unique technologies.

Precision BioSciences, a clinical stage gene editing company, today announced promotions and organizational changes that impact responsibilities within the company’s senior leadership team.

Precision Biosciences (NASDAQ:DTIL) is a biotech company with a proprietary gene-editing platform - ARCUS - 15 years in the making, and a promising genome editing endonuclease ...

Precision Biosciences has been on a roll with positive updates in both their CAR T-Cell and gene editing pipelines. Unfortunately, the market has yet to recognize the positive updates.

DURHAM, N.C., July 06, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS ...

A gene editing firm in the Triangle has landed a deal worth up to $1.4 billion with a global pharmaceutical company. Durham-based Precision BioSciences (Nasdaq: DTIL) has entered an agreement with ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of $60.00. Patrick Trucchio’s rating is based on ...